Jointown Pharmaceutical Group Co., Ltd (SHA:600998)
China · Delayed Price · Currency is CNY 5.05
-0.01 (-0.20%)
May 8, 2026, 3:00 PM CST
SHA:600998 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 164,156 | 161,390 | 151,695 | 149,981 | 140,282 | 122,359 |
Other Revenue | - | - | 115.13 | 158.54 | 142.16 | 48.09 |
| 164,156 | 161,390 | 151,810 | 150,140 | 140,424 | 122,407 | |
Revenue Growth (YoY) | 7.04% | 6.31% | 1.11% | 6.92% | 14.72% | 10.42% |
Cost of Revenue | 151,344 | 148,840 | 140,075 | 138,140 | 129,560 | 112,636 |
Gross Profit | 12,812 | 12,550 | 11,735 | 12,000 | 10,864 | 9,772 |
Selling, General & Admin | 8,298 | 8,105 | 7,229 | 7,193 | 6,637 | 6,097 |
Research & Development | 116.96 | 128.84 | 146.7 | 196.61 | 178.39 | 194.94 |
Other Operating Expenses | 246.8 | 272.78 | 413.12 | 425.65 | 98.16 | 293.01 |
Operating Expenses | 8,662 | 8,506 | 7,813 | 7,947 | 7,074 | 6,684 |
Operating Income | 4,150 | 4,043 | 3,923 | 4,053 | 3,790 | 3,087 |
Interest Expense | - | - | -1,284 | -1,318 | -1,221 | -1,145 |
Interest & Investment Income | 131.49 | 1,000 | 1,456 | 255.17 | 490.63 | 310.74 |
Currency Exchange Gain (Loss) | - | - | -0.81 | -4.34 | -17.05 | -6.65 |
Other Non Operating Income (Expenses) | -1,506 | -1,421 | -138.58 | -265.43 | -281.66 | -151.72 |
EBT Excluding Unusual Items | 2,776 | 3,623 | 3,955 | 2,721 | 2,760 | 2,094 |
Impairment of Goodwill | - | - | -10.85 | -1.18 | - | - |
Gain (Loss) on Sale of Investments | 165.47 | 51.9 | -98.35 | -78.4 | 1.44 | 1,235 |
Gain (Loss) on Sale of Assets | -7.25 | -244.27 | -425.83 | 5.11 | 45.67 | 6.72 |
Asset Writedown | -157.1 | -140.62 | - | - | - | -2.35 |
Other Unusual Items | - | - | 217.45 | 344.62 | 30.9 | 29.12 |
Pretax Income | 2,777 | 3,290 | 3,637 | 2,991 | 2,838 | 3,363 |
Income Tax Expense | 786.01 | 880.23 | 851.03 | 701.2 | 552.55 | 754.88 |
Earnings From Continuing Operations | 1,991 | 2,410 | 2,786 | 2,290 | 2,286 | 2,608 |
Minority Interest in Earnings | 27.28 | -154.72 | -279.05 | -115.62 | -200.57 | -160.05 |
Net Income | 2,018 | 2,255 | 2,507 | 2,174 | 2,085 | 2,448 |
Net Income to Common | 2,018 | 2,255 | 2,507 | 2,174 | 2,085 | 2,448 |
Net Income Growth | -31.34% | -10.07% | 15.33% | 4.27% | -14.84% | -20.38% |
Shares Outstanding (Basic) | 5,158 | 5,125 | 5,015 | 5,056 | 5,274 | 5,187 |
Shares Outstanding (Diluted) | 5,158 | 5,125 | 5,015 | 5,056 | 5,274 | 5,187 |
Shares Change (YoY) | 1.75% | 2.19% | -0.81% | -4.14% | 1.68% | -2.84% |
EPS (Basic) | 0.39 | 0.44 | 0.50 | 0.43 | 0.40 | 0.47 |
EPS (Diluted) | 0.39 | 0.44 | 0.50 | 0.43 | 0.40 | 0.47 |
EPS Growth | -32.53% | -12.00% | 16.28% | 8.78% | -16.25% | -18.06% |
Free Cash Flow | 2,432 | 2,039 | 2,107 | 3,699 | 2,743 | 2,073 |
Free Cash Flow Per Share | 0.47 | 0.40 | 0.42 | 0.73 | 0.52 | 0.40 |
Dividend Per Share | - | - | 0.200 | 0.194 | 0.186 | 0.112 |
Dividend Growth | - | - | 3.20% | 4.31% | 66.64% | -39.99% |
Gross Margin | 7.80% | 7.78% | 7.73% | 7.99% | 7.74% | 7.98% |
Operating Margin | 2.53% | 2.50% | 2.58% | 2.70% | 2.70% | 2.52% |
Profit Margin | 1.23% | 1.40% | 1.65% | 1.45% | 1.49% | 2.00% |
Free Cash Flow Margin | 1.48% | 1.26% | 1.39% | 2.46% | 1.95% | 1.69% |
EBITDA | 4,828 | 4,724 | 4,612 | 4,730 | 4,416 | 3,634 |
EBITDA Margin | 2.94% | 2.93% | 3.04% | 3.15% | 3.15% | 2.97% |
D&A For EBITDA | 677.91 | 680.26 | 689.68 | 676.96 | 626.41 | 547.21 |
EBIT | 4,150 | 4,043 | 3,923 | 4,053 | 3,790 | 3,087 |
EBIT Margin | 2.53% | 2.50% | 2.58% | 2.70% | 2.70% | 2.52% |
Effective Tax Rate | 28.31% | 26.76% | 23.40% | 23.45% | 19.47% | 22.45% |
Revenue as Reported | - | - | 151,810 | 150,140 | 140,424 | 122,407 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.